



**Rezurock (belumosudil)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





**Rezurock (belumosudil)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES: <input type="checkbox"/> graft-versus-host disease (chronic GVHD) <input type="checkbox"/> Other diagnosis: _____ ICD-10 _____		ICD-10:
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: <ul style="list-style-type: none"> <input type="checkbox"/> Does the patient have a diagnosis of Chronic Graft versus Host Disease (cGVHD)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Will the patient avoid concomitant therapy with all of the following? <ul style="list-style-type: none"> <input type="checkbox"/> Coadministration with proton-pump inhibitors (PPIs), or if therapy is unavoidable, the patient will be monitored closely for adverse reaction and dose modifications will be implemented; <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Coadministration with strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's Wort, etc.) or if therapy is unavoidable, the patient will be monitored closely for adverse reaction and/or dose modifications will be implemented <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Will the medication be used in combination with ibrutinib (subsequent therapy is allowed)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Is the patient post-allogeneic stem cell transplant (generally 3 or more months)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Does the patient have histologic relapse of underlying cancer or post-transplant lymphoproliferative disease? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Has the patient failed two or more previous lines of systemic therapy for the treatment of cGVHD (e.g., corticosteroids, immunosuppressants, etc.)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Is the medication being used in combination with stable doses of systemic therapies for GVHD, which can include corticosteroids (e.g., calcineurin inhibitors [cyclosporine; tacrolimus], sirolimus, mycophenolate mofetil, methotrexate, rituximab, etc.)? <input type="checkbox"/> Yes <input type="checkbox"/> No 		
If renewal: <ul style="list-style-type: none"> <input type="checkbox"/> Does the patient have absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include grade 4 hepatotoxicity, etc. <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Does the patient have response to therapy with an improvement in one or more of the following? <ul style="list-style-type: none"> <input type="checkbox"/> Clinician assessments (e.g., NIH Skin Score, Upper GI Response Score, NIH Lung Symptom Score, etc.) <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Patient-reported symptoms (e.g., Lee Symptom Scale, etc.) <input type="checkbox"/> Yes <input type="checkbox"/> No 		
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review? <hr/>		





**Rezurock (belumosudil)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program; c/o Magellan Health, Inc.
4801 E. Washington Street, Phoenix, AZ 85034
Phone: 877-228-7909

